Search Results - alena+gros

2 Results Sort By:
Improved Personalized Cancer Immunotherapy
Abstract: Scientists at NIH have identified a process to select highly tumor-reactive T cells from a patient tumor sample based on the expression of four specific T cell surface markers: programmed cell death protein 1 (PD-1; CD279), 4-1BB (CD137), T cell lg-and mucin-domain-containing molecule-3 (TIM-3), and/or lymphocyte activation gene 3 (LAG-3)....
Published: 4/8/2024   |   Inventor(s): Alena Gros, Steven Rosenberg
Keywords(s): adoptive cell transfer (ACT), T Cells, tumor infiltrating leukocytes (TIL)
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
Cancer-reactive T cells from Peripheral Blood
Abstract: Adoptive cell therapy (ACT) using genetically engineered T-cell receptors (TCRs) is a promising cancer treatment. These TCRs target genetic mutations unique to patients and play an important role in tumor regression. However, mutation-reactive T-cells and their TCRs can be difficult to identify and isolate from patients. Therefore, we need...
Published: 4/8/2024   |   Inventor(s): Alena Gros, Steven Rosenberg
Keywords(s): CANCER, Gros, Immunotherapy, mutation-reactive T-cells, Rosenberg, T-Cell Receptor, T-CELLS, TCR
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology